Effect of a mobile health program optimised with artificial intelligence (My Intelligent Cardiac Assistant—MICArdiac) on Systolic Blood Pressure and other cardiovascular risk factors in adults with high blood pressure: a multi-centre randomised controlled trial

niversity of Sydney0 sites500 target enrollmentJanuary 24, 2022

Overview

No summary available.

Registry

who.int

Start Date

January 24, 2022

End Date

TBD

Last Updated

3 years ago

Study Type

Interventional

Sex

All

Sponsor

•Participants are eligible if they meet all 3 of the following criteria and have no exclusion criteria.
•1\.Adults 35 years and over
•2\.Own a compatible smartphone – iPhone 5 onwards (iOS 10 and higher) or Android (6\.0 and higher).
•3\.Uncontrolled hypertension/high blood pressure (1 of the following):
•a)Known hypertension AND at least one recorded measure of SBP equal or above to 140mmHg and/or DBP equal or above to 90 mmHg in the last 12 months; OR
•b)At least one recorded measure of SBP equal or above to 160mmHg and/or DBP equal or above to 100 mmHg in the last 12 months; OR
•c)At least two recorded measures of SBP equal or above to 140mmHg and/or DBP equal or above to 90 mmHg in the last 12 months.

•History of cardiovascular disease, including peripheral artery disease, heart failure, coronary heart disease, stroke
•Have a pacemaker, defibrillator or other electrical implant not suited for use with provided wireless monitoring devices.
•Unable to use wearable/wireless monitoring devices provided
•Unable to complete the study procedures or follow\-up
•Unable to understand sufficient written English to provide informed consent
•Unable to provide informed consent
•Any condition that in the opinion of the responsible physician or investigator renders the patient unsuitable for the study (e.g. severe disability or significant memory or behavioural disorder)